Cefadroxil Powder, For Suspension
NDC Package 57237-098-01
Package Information
Cefadroxil powders is a medication used to treat a wide variety of bacterial infections. This formulation utilizes a powder, for suspension delivery system. Marketed by Rising Pharma Holdings, Inc., this product is identified by NDC 57237-098 and is authorized under FDA application ANDA065349.
Identification & Billing
- RxCUI: 105171 - cefadroxil 500 MG in 5 mL Oral Suspension
- RxCUI: 105171 - cefadroxil 100 MG/ML Oral Suspension
- RxCUI: 105171 - cefadroxil (as cefadroxil monohydrate) 100 MG/ML Oral Suspension
- RxCUI: 105171 - cefadroxil 500 MG per 5 ML Powder for Oral Suspension
- RxCUI: 309048 - cefadroxil 250 MG in 5 mL Oral Suspension
Clinical Specifications
Regulatory & Marketing
Hierarchy Structure
- 57237 - Rising Pharma Holdings, Inc.
- 57237-098 - Cefadroxil
- 57237-098-01 - 100 mL in 1 BOTTLE
- 57237-098 - Cefadroxil
The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.
* Please review the full disclaimer at the bottom of this page.
Other Available Packages
The following commercial packages are registered under the same Product NDC (57237-098). Click a package code to view its specific billing and regulatory data.
* Please review the full disclaimer at the bottom of this page.
Frequently Asked Questions
What is the distribution configuration for this product package?
The code 57237-098-01 identifies a specific commercial package of 100 ml in 1 bottle of Cefadroxil, a human prescription drug labeled by Rising Pharma Holdings, Inc.. This powder, for suspension is formulated for oral use and contains cefadroxil as the active substance.
Is this product currently listed with the FDA?
Yes, this product is active and verified within the NDC Directory. It was introduced to the market by Rising Pharma Holdings, Inc. on April 25, 2013. The current certification is valid through December 31, 2026.
What are the primary indications for this medication?
This medication is used to treat a wide variety of bacterial infections. It belongs to a class of drugs known as cephalosporin antibiotics. It works by stopping the growth of bacteria. This antibiotic treats only bacterial infections. It will not work for viral infections (such as common cold, flu). Using any antibiotic when it is not needed can cause it to not work for future infections.
How is this Rising Pharma Holdings, Inc. product billed for insurance claims?
For medical billing and reimbursement, this package follows the 11-digit CMS format: 57237009801. Quantities are measured in per "ml or milliliter", products billed per milliliter are usually products measured by liquid volume.. There are 100 total billable units per package. The table below illustrates the segment conversion from the 10-digit labeler code to the 11-digit provider format.
11-Digit Code Conversion
Billing payers usually require a 5-4-2 segment configuration. Below is the conversion from the 10-digit package format to the 11-digit billing format:
Note: The zero is added to the Product segment to maintain the 5-4-2 structure.